Current Portfolio

Flagship invests in three principle business sectors: Therapeutics; Health Technologies; and Sustainability/Clean Technology. Initial investments range between $250 thousand and $5 million, and we may invest up to $12-15 million during the life of a company. Click on a tab below to filter the listing of the portfolio by industry sector, or on a column heading to sort.

Company Description Status Initial Datesort icon
<a href="/venture-capital/all-companies/joule-unlimited-inc">Joule Unlimited, Inc.</a> Pioneering a CO2-to-fuel production platform, effectively reversing combustion through the use of solar energy. Private 2007 View Profile
<a href="/venture-capital/all-companies/seventh-sense-biosystems-inc">Seventh Sense Biosystems, Inc.</a> Developing an array of products based on the company's proprietary TAP™ (Touch Activated Phlebotomy) painless blood collection platform. Private 2007 View Profile
<a href="/venture-capital/all-companies/bind-therapeutics-inc">BIND Therapeutics, Inc.</a> Developing Accurins, its novel targeted therapeutics. Public 2007 View Profile
<a href="/venture-capital/all-companies/novomer-inc">Novomer, Inc.</a> Commercializing a family of low-cost, high-performance, sustainable polymers and other chemicals. Private 2007 View Profile
<a href="/venture-capital/all-companies/quanterix-corporation">Quanterix Corporation</a> Developing ground-breaking tools in high definition diagnostics. Private 2007 View Profile
<a href="/venture-capital/all-companies/concert-pharmaceuticals-inc">Concert Pharmaceuticals, Inc.</a> Applying the company’s DCE Platform® (deuterated chemical entity platform) to create novel and differentiated small molecule drugs. Public 2006 View Profile
<a href="/venture-capital/all-companies/t2-biosystems-inc">T2 Biosystems, Inc.</a> Using T2MR to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare. Public 2006 View Profile
<a href="/venture-capital/all-companies/mascoma-corporation">Mascoma Corporation</a> Leading technology for the conversion of biomass to fuels and chemicals. Private 2006 View Profile
<a href="/venture-capital/all-companies/acceleron-pharma-inc">Acceleron Pharma, Inc.</a> Discovering, developing and commercializing novel protein therapeutics for cancer and rare diseases. Public 2004 View Profile
<a href="/venture-capital/all-companies/black-duck-software-inc">Black Duck Software, Inc.</a> Providing the world’s only end-to-end platform for OSS Logistics. Private 2004 View Profile
<a href="/venture-capital/all-companies/ensemble-therapeutics-corporation">Ensemble Therapeutics Corporation</a> Deploying its proprietary chemistry platforms to develop a novel class of therapeutics known as “Ensemblins”. Private 2004 View Profile
<a href="/venture-capital/all-companies/seahorse-bioscience-inc">Seahorse Bioscience, Inc.</a> XF instruments are the industry standard in cellular bioenergetic measurements. Private 2001 View Profile
<a href="/venture-capital/all-companies/selventa">Selventa</a> Pioneering the development of Systems Diagnostics (SysDx™). Private 2001 View Profile
<a href="/venture-capital/all-companies/affinnova-inc">Affinnova, Inc.</a> Improving innovation and marketing success rates. Private 2000 View Profile
<a href="/venture-capital/all-companies/bg-medicine-inc">BG Medicine, Inc.</a> Developing and delivering diagnostic solutions to aid in the clinical management of heart failure and related disorders. Public 2000 View Profile